Precision medicine developer Metabolon has now raised $80m since 2000, and its earlier investors include Sumitomo and Syngenta.
Metabolon, a US-based metabolomics technology developer backed by agribusiness Syngenta and conglomerate Sumitomo, has closed $15m in financing from healthcare-focused growth equity firm Essex Woodlands.
Founded in 2000, Metabolon is developing health assessment platforms and systems that use metabolomics for precision medicine and biomarker research and new kinds of diagnostic tests.
The funding will go to advancing the precision medicine products the company is developing. Essex Woodlands has the option to invest a further $10m in Metabolon which would be…
